leukemia/tyrosine

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 334 výsledky

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The primary objective of this study is to determine the plasma pharmacokinetics (PK) of quizartinib and its pharmacologically active metabolite AC886 after a single oral dose of 30 mg in participants with moderate hepatic impairment (HI) (as defined by National Cancer Institute-Organ Dysfunction

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

All eligible subjects must be relapsed or refractory to at least 2 prior lines of therapy, one of which must have included an inhibitor of B-cell receptor signaling (approved Bruton's tyrosine kinase inhibitor [BTKi] or Phosphoinositide 3-kinase inhibitor [PI3Ki]) or venetoclax. The dose escalation

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Donafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML). Donafenib is therefore a promising candidate for improvement of chemotherapy results in AML. This clinical trial evaluates the safety and pharmacokinetics of

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients. Besides age, the genetic configuration of AML blasts is one of the strongest prognostic factors. Patients with mutations in the core-binding factor (CBF) genes have the best prognosis, however a considerable

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Flumatinib + hyper-CVAD (younger than 60): Induction therapy: Flumatinib 600mg per day, on an empty stomach; For cycles 1, 3, 5, and 7: cyclophosphamide (CTX) 300 mg/m² is given intravenously over 3 h every 12 h for six doses on days 1-3; a continuous daily infusion of sodium mercaptoethanesulfonate

The EMPATHY Pilot Study

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The evolution in the understanding of the biology of Chronic Myeloid Leukemia (CML), that eventually translated into highly effective molecular targeted therapies, is unparalleled in cancer medicine. This knowledge led the development of a number of orally active molecule tyrosine kinase inhibitors

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

PRE-PHASE: Patients may receive corticosteroids and/or hydroxyurea at the discretion of the treating physician prior to beginning induction therapy. A seven-day corticosteroid pre-phase, which can include days of corticosteroid receipt prior to protocol registration, will precede initiation of TKI

Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Levine et al., 2007). According to WHO 2016 classification which also included chronic

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This study is being conducted in three parts: Phase Ia, Phase Ib and Phase II, disease-specific expansion cohorts. Phase Ia explored escalating doses of a monotherapy of a novel Bruton's Tyrosine Kinase (BTK) inhibitor, DTRMWXHS-12. Phase Ib explored two combination therapies, DTRM-505 (DTRMWXHS-12

A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

ALLTogether is a European clinical treatment study for acute lymphoblastic leukaemia (ALL) in children and young adults. The aims are to improve survival and quality of survival for children and young adults with ALL. In young people, ALL has excellent outcome with an overall survival of about 92%

Immunophenotyping and Xist Gene in AML

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood. with high mortality and variable prognosis. AML is the most common acute leukemia in adults, accounting for ~ 80 percent of cases in

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Gene Expression Profiles in CML Non-responders

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The aim of this project is to use gene expression microarrays to detect expression profiles which may be associated with TKI resistance in order to better stratify CML patients and allow a more targeted approach to therapy. The project may also help elucidate the mechanism of resistance in those

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

PRIMARY OBJECTIVE: I. To determine the clinical activity of the combination of asciminib (ABL001) and a tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML) in complete cytogenetic response (CCyR) but detectable BCR-ABL1 transcript. SECONDARY OBJECTIVES: I. To determine

Predchádzajúce
1
2
3
4
5
6
...
22
23
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume